Promethean BioPharma supports the rescheduling of psilocybin and MDMA in Australia
Updated: Mar 8, 2022
Promethean BioPharma supports the work of Mind Medicine Australia and encourages their submissions to the Therapeutic Goods Administration in relation to the rescheduling of psilocybin and MDMA from Schedule 9 to Schedule 8.
For more information:
https://mindmedicineaustralia.org.au/